Anti-Fibrosis Compound

Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. The causes of fibrosis can be radiation, chemotherapy, burns, or an improper treatment of lymphedema. In fibrosis, the tissues are damaged because the scar-like structures prevent tissue fluid from bringing essential nutrients to the cells. This produces increased toxic waste products surrounding the cells within these tissues. Muscles with significant fibrosis have less strength and flexibility and operate with less efficiency compared to normal muscles.

The main types of fibrosis are Cystic Fibrosis (CF) and Idiopathic Pulmonary Fibrosis (IPF). The global IPF market was valued at USD 2.0 billion in 2009, and it is expected to increase with a compound annual growth rate of 25.1% from 2009 to 2016. The US market for CF is projected to exceed USD 896 million by 2015.

The main advantages of the compound in the inventions are as follows:

Long half life, which implies lesser dosage is needed compared with other compounds

Much higher relative activity compared to other compounds

Low relative toxicity and very high safety index